Literature DB >> 29146227

Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity.

Christian Abendstein Kjellmo1, Helen Karlsson2, Torunn K Nestvold3, Stefan Ljunggren2, Karin Cederbrant4, Maritha Marcusson-Ståhl4, Monica Mathisen5, Knut Tore Lappegård6, Anders Hovland6.   

Abstract

BACKGROUND: Bariatric surgery has been shown to reduce cardiovascular events and cause-specific mortality for coronary artery disease in obese patients. Lipoprotein biomarkers relating to low-density lipoprotein (LDL), high-density lipoprotein (HDL), their subfractions, and macrophage cholesterol efflux have all been hypothesized to be of value in cardiovascular risk assessment.
OBJECTIVES: The objective of this study was to examine the effect of a lifestyle intervention followed by bariatric surgery on the lipid profile of morbidly obese patients.
METHODS: Thirty-four morbidly obese patients were evaluated before and after lifestyle changes and then 1 year after bariatric surgery. They were compared with 17 lean subjects. Several lipoprotein metrics, serum amyloid A (SAA), serum paraoxonase-1 (PON1), and macrophage cholesterol efflux capacity (CEC) were assessed.
RESULTS: Average weight loss after the lifestyle intervention was 10.5% and 1 year after bariatric surgery was 33.9%. The lifestyle intervention significantly decreased triglycerides (TGs; -28.7 mg/dL, P < .05), LDL cholesterol (LDL-C; -32.3 mg/dL, P < .0001), and apolipoprotein B (apoB; -62.9 μg/mL, P < .001). Bariatric surgery further reduced TGs (-36.7 mg/dL, P < .05), increased HDL cholesterol (+12 mg/dL, P < .0001), and reductions in LDL-C and apoB were sustained. Bariatric surgery reduced large, buoyant LDL (P < .0001), but had no effect on the small, dense LDL. The large HDL subfractions increased (P < .0001), but there was no effect on the smaller HDL subfractions. The ratio for SAA/PON1 was reduced after the lifestyle intervention (P < .01) and further reduced after bariatric surgery (P < .0001). Neither the lifestyle intervention nor bariatric surgery had any effect on CEC.
CONCLUSIONS: Lifestyle intervention followed by bariatric surgery in 34 morbidly obese patients showed favorable effects on TGs, LDL-C, and apoB. HDL cholesterol and apoA1 was increased, apoB/apoA1 ratio as well as SAA/PON1 ratio reduced, but bariatric surgery did not influence CEC.
Copyright © 2017 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bariatric surgery; Cholesterol efflux capacity; Lipoprotein particle subclasses; Obesity; Paraoxonase-1 (PON1); Serum amyloid A (SAA)

Mesh:

Substances:

Year:  2017        PMID: 29146227     DOI: 10.1016/j.jacl.2017.10.007

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  11 in total

1.  Circulating Lipoproteins in Subjects with Morbid Obesity Undergoing Bariatric Surgery with Gastric Bypass or Sleeve Gastrectomy.

Authors:  Jan O Aaseth; Helge Rootwelt; Kjetil Retterstøl; Knut Hestad; Per G Farup
Journal:  Nutrients       Date:  2022-06-08       Impact factor: 6.706

2.  Effect of Bariatric Surgery on High-Density Lipoprotein (HDL) Cholesterol in Non-diabetic Patients with Severe Obesity.

Authors:  Otto Henrique Nienov; Fernanda Dapper Machado; Lisiane Stefani Dias; Luiz Alberto De Carli; Helena Schmid
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

3.  Phosphatidylcholine and its relation to apolipoproteins A-1 and B changes after Roux-en-Y gastric bypass: a cohort study.

Authors:  Elin Rebecka Carlsson; Kristine H Allin; Sten Madsbad; Mogens Fenger
Journal:  Lipids Health Dis       Date:  2019-09-05       Impact factor: 3.876

Review 4.  Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function.

Authors:  Julia T Stadler; Gunther Marsche
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

5.  Metal additive manufacturing and possible clinical markers for the monitoring of exposure-related health effects.

Authors:  Stefan A Ljunggren; Liam J Ward; Pål Graff; Anders Persson; Malin Leijon Lind; Helen Karlsson
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

6.  Improvements in cholesterol efflux capacity of HDL and adiponectin contribute to mitigation in cardiovascular disease risk after bariatric surgery in a cohort with morbid obesity.

Authors:  Himani Thakkar; Vinnyfred Vincent; Sakshi Sukhla; Manraj Sra; Uma Kanga; Sandeep Aggarwal; Archna Singh
Journal:  Diabetol Metab Syndr       Date:  2021-04-17       Impact factor: 3.320

7.  Bariatric Surgery Improves HDL Function Examined by ApoA1 Exchange Rate and Cholesterol Efflux Capacity in Patients with Obesity and Type 2 Diabetes.

Authors:  Shuhui Wang Lorkowski; Gregory Brubaker; Daniel M Rotroff; Sangeeta R Kashyap; Deepak L Bhatt; Steven E Nissen; Philip R Schauer; Ali Aminian; Jonathan D Smith
Journal:  Biomolecules       Date:  2020-04-04

8.  Physical Activity Improves Lipid and Weight-Loss Outcomes After Metabolic Bariatric Surgery in Adolescents with Severe Obesity.

Authors:  Paula Holland Price; Alexander M Kaizer; Stephen R Daniels; Todd M Jenkins; Thomas H Inge; Robert H Eckel
Journal:  Obesity (Silver Spring)       Date:  2019-05-03       Impact factor: 5.002

9.  Bariatric surgery and LDL cholesterol (BASALTO) trial study protocol: randomised controlled study evaluating the effect of gastric bypass versus sleeve gastrectomy on high LDL cholesterol.

Authors:  David Benaiges; Albert Goday; Juana A Flores-Le Roux; Montserrat Fitó; Oscar Pozo; Jose Rodríguez-Morató; Carme Serra; Manuel Pera; Gemma Llauradó; Elisenda Climent; Olga Castañer; Jose M Ramon; Juan Pedro-Botet
Journal:  BMJ Open       Date:  2020-09-10       Impact factor: 2.692

Review 10.  High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.

Authors:  Maria Pia Adorni; Nicoletta Ronda; Franco Bernini; Francesca Zimetti
Journal:  Cells       Date:  2021-03-05       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.